Iron metabolism, free radicals, and oxidative injury.

Iron has the capacity to accept and donate electrons readily. This capability makes it physiologically essential, as a useful component of cytochromes and oxygen-binding molecules. However, iron is also biochemically dangerous; it can damage tissues by catalyzing the conversion of hydrogen peroxide to free-radical ions that attack cellular membranes, protein and DNA. This threat is reduced in the healthy state where, because of the fine iron metabolism regulation, there is never appreciable concentration of 'free iron'. Under pathological conditions, iron metabolism and superoxide metabolism are clearly interactive. Each can exacerbate the toxicity of the other. Iron overload may amplify the damaging effects of superoxide overproduction in a very broad spectrum of inflammatory, both acute and chronic, conditions. Furthermore, chronic oxidative stress may modulate iron uptake and storage, leading to a self-sustained and ever-increasing spiral of cytotoxic and mutagenic events. The iron chelator deferroxamine is able to chelate 'free iron' even inside the cell. Its regular clinical use is to promote the excretion of an iron overload, when phlebotomy is harmful, and the dosage varies between 2-10 g/d. In conditions where deferroxamine is used to prevent the iron-driven oxygen toxicity, i.e., acute or chronic inflammatory diseases with oxidative stress, the dosage can be extremely reduced and the addition of antioxidants could be useful.

[1]  D. Fuchs,et al.  Linkage of cell-mediated immunity to iron metabolism. , 1995, Immunology today.

[2]  A. Rubinstein,et al.  Ferritin levels in pediatric HIV‐1 infection , 1994, Acta paediatrica.

[3]  Gregory J. Anderson,et al.  Hephaestin, a ceruloplasmin homologue implicated in intestinal iron transport, is defective in the sla mouse , 1999, Nature Genetics.

[4]  M. Mizokami,et al.  A pilot randomized, controlled trial of the effect of iron depletion on long-term response to α-interferon in patients with chronic hepatitis C , 1998 .

[5]  W. Irish,et al.  Response to interferon α therapy is influenced by the iron content of the liver , 1994 .

[6]  M. Hentze,et al.  Pathways for the regulation of macrophage iron metabolism by the anti-inflammatory cytokines IL-4 and IL-13. , 1997, Journal of immunology.

[7]  R. Kohen,et al.  Paraquat toxicity is enhanced by iron and reduced by desferrioxamine in laboratory mice. , 1985, Biochemical pharmacology.

[8]  R. Ulvik,et al.  On the limited ability of superoxide to release iron from ferritin. , 1990, European journal of biochemistry.

[9]  J. Drapier,et al.  Interplay between ferritin metabolism, reactive oxygen species and nitric oxide , 1997, JBIC Journal of Biological Inorganic Chemistry.

[10]  R. T. Drew,et al.  Failure of desferrioxamine to modify the toxicity of paraquat in rats. , 1985, Journal of free radicals in biology & medicine.

[11]  N. Andrews Disorders of iron metabolism. , 1999, The New England journal of medicine.

[12]  J. Sullivan IRON AND THE SEX DIFFERENCE IN HEART DISEASE RISK , 1981, The Lancet.

[13]  M. Mollet,et al.  Phase II trial of copper zinc superoxide dismutase (CuZnSOD) in treatment of Crohn's disease. , 1989, Free radical biology & medicine.

[14]  I. Cabantchik,et al.  Fluorescence analysis of the labile iron pool of mammalian cells. , 1997, Analytical biochemistry.

[15]  M. Noordermeer,et al.  Iron release from human monocytes after erythrophagocytosis in vitro: an investigation in normal subjects and hereditary hemochromatosis patients. , 1998, Blood.

[16]  P. Aisen,et al.  Iron metabolism in the erythrophagocytosing Kupffer cell , 1988, Hepatology.

[17]  C. Babbs Free radicals and the etiology of colon cancer. , 1990, Free radical biology & medicine.

[18]  A. Borghi,et al.  Iron removal therapy in porphyria cutanea tarda: phlebotomy versus slow subcutaneous desferrioxamine infusion , 1986, The British journal of dermatology.

[19]  G. Mancia,et al.  Hepatic iron overload in patients with chronic viral hepatitis: Role of HFE gene mutations , 1998, Hepatology.

[20]  P. Brissot,et al.  Liver iron concentration and distribution in chronic hepatitis C before and after interferon treatment. , 1997, Gut.

[21]  J. Grove,et al.  Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C , 1998, Hepatology.

[22]  P. Cutler Deferoxamine Therapy in High-Ferritin Diabetes , 1989, Diabetes.

[23]  V. Paradis,et al.  In situ detection of lipid peroxidation in chronic hepatitis C: correlation with pathological features. , 1997, Journal of clinical pathology.

[24]  M. Comporti,et al.  Allyl alcohol-induced hemolysis and its relation to iron release and lipid peroxidation. , 1989, Biochemical pharmacology.

[25]  H. Bonkovsky,et al.  Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: A multicenter, prospective, randomized, controlled trial , 2000, Hepatology.

[26]  J. Delanghe,et al.  Biological and clinical significance of haptoglobin polymorphism in humans. , 1996, Clinical chemistry.

[27]  B. Halliwell,et al.  Superoxide-dependent formation of hydroxyl radicals and lipid peroxidation in the presence of iron salts. Detection of 'catalytic' iron and anti-oxidant activity in extracellular fluids. , 1982, The Biochemical journal.

[28]  P. Rebulla,et al.  Serum ferritin, desferrioxamine, and evolution of HIV-1 infection in thalassemic patients. , 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[29]  Á. Remacha,et al.  Prevalence of high serum and red cell ferritin levels in HIV-infected patients. , 1994, Haematologica.

[30]  J. McCord,et al.  Iron, Oxygen Radicals, and Disease , 1998 .

[31]  A. Brownlie,et al.  Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter , 2000, Nature.

[32]  H. Bonkovsky,et al.  Iron and the liver. , 1991, The American journal of the medical sciences.

[33]  P. Harrison,et al.  The ferritins: molecular properties, iron storage function and cellular regulation. , 1996, Biochimica et biophysica acta.

[34]  D. Parry,et al.  Effect of iron chelation therapy on recovery from deep coma in children with cerebral malaria. , 1992, The New England journal of medicine.

[35]  H. Rouach,et al.  Involvement of iron and iron-catalyzed free radical production in ethanol metabolism and toxicity. , 1987, Enzyme.

[36]  D. Wyler Bark, weeds, and iron chelators--drugs for malaria. , 1992, The New England journal of medicine.

[37]  S. Toyokuni,et al.  Iron-induced carcinogenesis: the role of redox regulation. , 1996, Free radical biology & medicine.

[38]  R D Klausner,et al.  Structure and dynamics of the iron responsive element RNA: implications for binding of the RNA by iron regulatory binding proteins. , 1997, Journal of molecular biology.

[39]  M. Pippard,et al.  Iron Metabolism in Health and Disease , 1994 .

[40]  C. Achim,et al.  Haptoglobin polymorphism, iron metabolism and mortality in HIV infection , 1998 .